Page 112 - 《中国药房》2022年4期

study[J]. Lancet Oncol，2020，21（4）：519-530. [19] ZHANG H H，ZHANG Y D，HUANG C N，et al. Cost-ef-
[ 7 ] 中国临床肿瘤学会指南工作委员会组织.中国临床肿瘤 fectiveness analysis of trastuzumab emtansine as second-
学会（CSCO）乳腺癌诊疗指南：2020[S].北京：人民卫生 line therapy for HER2-positive breast cancer in China[J].
出版社，2020：79-83. Clin Drug Investig，2021，41（6）：569-577.
[ 8 ] CHENG L J，LOKE L，LIM E H，et al. Cost-effectiveness [20] LI N，ZHENG H R，HUANG Y L，et al. Cost-effective-
of pertuzumab and trastuzumab biosimilar combination ness analysis of olaparib maintenance treatment for germ-
therapy as initial treatment for HER2-positive metastatic line BRCA-mutated metastatic pancreatic Cancer[J]. Front
breast cancer in Singapore[J]. Expert Rev Pharmacoecon Pharmacol，2021，12：632818.
Outcomes Res，2021，21（3）：449-456. [21] WU B，LI T，CAI J，et al. Cost-effectiveness analysis of
[ 9 ] PETROU P. A systematic review of economic evaluations adjuvant chemotherapies in patients presenting with gas-
of tyrosine kinase inhibitors of vascular endothelial tric cancer after D2 gastrectomy[J]. BMC Cancer，2014，
growth factor receptors，mammalian target of rapamycin 14：984.
inhibitors and programmed death-1 inhibitors in metasta- [22] WANG H，ZENG C X，LI X，et al. Cost-utility of afatinib
tic renal cell cancer[J]. Expert Rev Pharmacoecon Out- and gefitinib as first-line treatment for EGFR-mutated ad-
comes Res，2018，18（3）：255-265. vanced non-small-cell lung cancer[J]. Future Oncol，2019，
[10] LATIMER N R. Survival analysis for economic evalua- 15（2）：181-191.
tions alongside clinical trials：extrapolation with pa- [23] ZHOU K X，JIANG C L，LI Q. Cost-effectiveness analy-
tient-level data：inconsistencies，limitations，and a practi- sis of pembrolizumab monotherapy and chemotherapy in
cal guide[J]. Med Decis Making，2013，33（6）：743-754. the non-small-cell lung cancer with different PD-L1 tumor
[11] GUYOT P，ADES A E，OUWENS M J N M，et al. proportion scores[J]. Lung Cancer，2019，136（9）：98-101.
Enhanced secondary analysis of survival data：reconstructing [24] 中国居民营养与慢性病状况报告：2020年[J].营养学报，
the data from published Kaplan-Meier survival curves[J]. 2020，42（6）：521.
BMC Med Res Methodol，2012，12：9. [25] LLOYD A，NAFEES B，NAREWSKA J，et al. Health
[12] GAO F，LANGUILLE C，KARZAZI K，et al. Efficiency state utilities for metastatic breast cancer[J]. Br J Cancer，
of fine scale and spatial regression in modelling associa- 2006，95（6）：683-690.
tions between healthcare service spatial accessibility and [26] NAFEES B，LLOYD A J，DEWILDE S，et al. Health state
their utilization[J]. Int J Health Geogr，2021，20（1）：22. utilities in non-small cell lung cancer：an international
[13] 邵荣杰，唐文熙，马爱霞.分区生存模型在药物经济学评 study[J]. Asia Pac J Clin Oncol，2017，13（5）：e195-e203.
价中的应用[J].中国卫生经济，2019，38（9）：60-63. [27] BRIGGS A H，WEINSTEIN M C，FENWICK E A，et al.
[14] 刘国恩.中国药物经济学评价指南2020[S].北京：中国市 Model parameter estimation and uncertainty analysis：a re-
场出版社，2020：27-46. port of the ISPOR-SMDM modeling good research prac-
[15] EICHLER H G，KONG S X，GERTH W C，et al. Use of tices task force working group-6[J]. Med Decis Making，
cost-effectiveness analysis in health-care resource alloca- 2012，32（5）：722-732.
tion decision-making：how are cost-effectiveness thre- [28] MORIWAKI K，UECHI S，FUJIWARA T，et al. Econo-
sholds expected to emerge? [J]. Value Health，2004，7（5）： mic evaluation of first-line pertuzumab therapy in patients
518-528. with HER2-positive metastatic breast cancer in Japan[J].
[16] 国家统计局.国家数据[EB/OL]. [2021-08-06]. https：//da- Pharmacoecon Open，2021，5（3）：437-447.
ta.stats.gov.cn/. [29] LATIMER N R. Survival analysis for economic evalua-
[17] NCI. NCI common terminology criteria for adverse events tions alongside clinical trials：extrapolation with pa-
（CTCAE）version 4.0[EB/OL].[2021-07-25]. https：//ctep. tient-level data：inconsistencies，limitations，and a practi-
cancer.gov/protocolDevelopment/electronic_applications/ cal guide[J]. Med Decis Making，2013，33（6）：743-754.
ctc.htm. （收稿日期：2021-08-17 修回日期：2021-12-27）
[18] 药智数据.药品中标信息查询[EB/OL]. [2021-08-06]. （编辑：邹丽娟）
https：//db.yaozh.com/yaopinzhongbiao.

·486 · China Pharmacy 2022 Vol. 33 No. 4 中国药房 2022年第33卷第4期